Natural and synthetic polymers as inhibitors of drug efflux pumps

Pharmaceutical Research

Volumn 25, Issue 3, 2008, Pages 500-511

  Werle, Martin ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Drug delivery; Efflux pump inhibitors; P glycoprotein; P gp inhibitors; Polymeric inhibitors

Indexed keywords

ALGINIC ACID; AMPHOPHILE; ANIONIC SURFACTANT; ANTINEOPLASTIC AGENT; ASCOPHYLLUM EXTRACT; COPOLYMER; DENDRIMER; DOXORUBICIN; ETHYLENE OXIDE; GELLAN; MACROGOL 20000; MACROGOL DERIVATIVE; MACROGOL STEARATE; NATURAL PRODUCT; PACLITAXEL; PEG 300; PLANT EXTRACT; POLOXAMER; POLYMER; POLYSACCHARIDE; POLYSORBATE; POLYSORBATE 40; POLYSORBATE 80; PROPRANOLOL DERIVATIVE; PROPYLENE OXIDE; SURFACTANT; TPGS 1000; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; XANTHAN;

ASCOPHYLLUM; CANCER CLASSIFICATION; CANCER THERAPY; CELL LEVEL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 40549125358     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9347-8     Document Type: Review

References (98)

1. 1. R. L. Juliano V. Ling 1976 A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 152 162 990323 10.1016/0005-2736(76)90160-7 1:CAS:528:DyaE28XlvV2qs70%3D R. L. Juliano and V. Ling. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152–162 (1976).
2. 2. F. Thiebaut T. Tsuruo H. Hamada M. M. Gottesman I. Pastan M. C. Willingham 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U. S. A. 84 7735 7738 2444983 10.1073/pnas.84.21.7735 1:CAS:528:DyaL2sXmtlels7k%3D F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84:7735–7738 (1987).
3. 3. C. Cordon-Cardo J. P. O’Brien J. Boccia D. Casals J. R. Bertino M. R. Melamed 1990 Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J. Histochem. Cytochem. 38 1277 1287 1974900 1:CAS:528:DyaK3cXlsV2ktbY%3D C. Cordon-Cardo, J. P. O’Brien, J. Boccia, D. Casals, J. R. Bertino, and M. R. Melamed. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277–1287 (1990).
4. 4. F. Girardin 2006 Membrane transporter proteins: a challenge for CNS drug development Dialogues Clin. Neurosci. 8 311 321 17117613 F. Girardin. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci. 8:311–321 (2006).
5. 5. S. Majumdar S. Duvvuri A. K. Mitra 2004 Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development Adv. Drug Deliv. Rev. 56 1437 1452 15191791 10.1016/j.addr.2004.02.006 1:CAS:528:DC%2BD2cXkvVCrtL4%3D S. Majumdar, S. Duvvuri, and A. K. Mitra. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 56:1437–1452 (2004).
6. 6. M. V. Varma O. P. Perumal R. Panchagnula 2006 Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery Curr. Opin. Chem. Biol. 10 367 373 16814593 10.1016/j.cbpa.2006.06.015 1:CAS:528:DC%2BD28XntlGitbk%3D M. V. Varma, O. P. Perumal, and R. Panchagnula. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr. Opin. Chem. Biol. 10:367–373 (2006).
7. 7. A. Tsuji 1998 P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier Ther. Drug Monit. 20 588 590 9780140 10.1097/00007691-199810000-00024 1:CAS:528:DyaK1cXmvFKhsrc%3D A. Tsuji. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther. Drug Monit. 20:588–590 (1998).
8. 8. H. Goldberg V. Ling P. Y. Wong K. Skorecki 1988 Reduced cyclosporin accumulation in multidrug-resistant cells Biochem. Biophys. Res. Commun. 152 552 558 2896500 10.1016/S0006-291X(88)80073-1 1:CAS:528:DyaL1cXktVSht7o%3D H. Goldberg, V. Ling, P. Y. Wong, and K. Skorecki. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 152:552–558 (1988).
9. 9. C. P. Yang S. G. DePinho L. M. Greenberger R. J. Arceci S. B. Horwitz 1989 Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus J. Biol. Chem. 264 782 788 2562956 1:CAS:528:DyaL1MXmvFGqsQ%3D%3D C. P. Yang, S. G. DePinho, L. M. Greenberger, R. J. Arceci, and S. B. Horwitz. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem. 264:782–788 (1989).
10. 10. K. Yusa T. Tsuruo 1989 Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells Cancer Res. 49 5002 5006 2569930 1:CAS:528:DyaL1MXls1KqsL0%3D K. Yusa and T. Tsuruo. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49:5002–5006 (1989).
11. 11. J. Karlsson S. M. Kuo J. Ziemniak P. Artursson 1993 Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein Br. J. Pharmacol. 110 1009 1016 7905337 1:CAS:528:DyaK2cXitlSmsA%3D%3D J. Karlsson, S. M. Kuo, J. Ziemniak, and P. Artursson. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009–1016 (1993).
12. 12. I. A. Lannoy de M. Silverman 1992 The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin Biochem. Biophys. Res. Commun. 189 551 557 1360207 10.1016/0006-291X(92)91593-F I. A. de Lannoy and M. Silverman. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189:551–557 (1992).
13. 13. D. Leveque F. Jehl 1995 P-glycoprotein and pharmacokinetics Anticancer Res. 15 331 336 7763002 1:CAS:528:DyaK2MXmslWjurw%3D D. Leveque and F. Jehl. P-glycoprotein and pharmacokinetics. Anticancer Res. 15:331–336 (1995).
14. 14. S. Choudhuri C. D. Klaassen 2006 Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters Int. J. Toxicol. 25 231 259 16815813 10.1080/10915810600746023 1:CAS:528:DC%2BD28XotVWnsLg%3D S. Choudhuri and C. D. Klaassen. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25:231–259 (2006).
15. 15. M. Mazel P. Clair C. Rousselle P. Vidal J. M. Scherrmann D. Mathieu J. Temsamani 2001 Doxorubicin–peptide conjugates overcome multidrug resistance Anticancer Drugs 12 107 116 11261883 10.1097/00001813-200102000-00003 1:CAS:528:DC%2BD3MXhvVKnsrw%3D M. Mazel, P. Clair, C. Rousselle, P. Vidal, J. M. Scherrmann, D. Mathieu, and J. Temsamani. Doxorubicin–peptide conjugates overcome multidrug resistance. Anticancer Drugs 12:107–116 (2001).
16. 16. T. J. Raub 2006 P-glycoprotein recognition of substrates and circumvention through rational drug design Mol. Pharmacol. 3 3 25 10.1021/mp0500871 1:CAS:528:DC%2BD2MXhtlagu7%2FP T. J. Raub. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharmacol. 3:3–25 (2006).
17. 17. M. V. Varma Y. Ashokraj C. S. Dey R. Panchagnula 2003 P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement Pharmacol. Res. 48 347 359 12902205 10.1016/S1043-6618(03)00158-0 1:CAS:528:DC%2BD3sXlvFOktbc%3D M. V. Varma, Y. Ashokraj, C. S. Dey, and R. Panchagnula. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48:347–359 (2003).
18. 18. M. V. Varma R. Panchagnula 2005 Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur. J. Pharm. Sci. 25 445 453 15890503 10.1016/j.ejps.2005.04.003 1:CAS:528:DC%2BD2MXlsVCltbg%3D M. V. Varma and R. Panchagnula. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25:445–453 (2005).
19. 19. B. J. Aungst 2000 Intestinal permeation enhancers J. Pharm. Sci. 89 429 442 10737905 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J 1:CAS:528:DC%2BD3cXis12ktbw%3D B. J. Aungst. Intestinal permeation enhancers. J. Pharm. Sci. 89:429–442 (2000).
20. 20. A. Bernkop-Schnürch 1998 The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins J. Control. Release 52 1 16 9685931 10.1016/S0168-3659(97)00204-6 A. Bernkop-Schnürch. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52:1–16 (1998).
21. 21. H. L. Luessen C. O. Rentel A. F. Kotzé C.-M. Lehr A. G. deBoer J. C. Verhoef H. E. Junginger 1997 Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro J. Control. Release 45 15 23 10.1016/S0168-3659(96)01536-2 1:CAS:528:DyaK28XntlOgs7Y%3D H. L. Luessen, C. O. Rentel, A. F. Kotzé, C.-M. Lehr, A. G. deBoer, J. C. Verhoef, and H. E. Junginger. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release 45:15–23 (1997).
22. 22. S. A. Galindo-Rodriguez E. Allemann H. Fessi E. Doelker 2005 Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies Crit. Rev. Ther. Drug Carr. Syst. 22 419 464 1:CAS:528:DC%2BD28XkslSksA%3D%3D S. A. Galindo-Rodriguez, E. Allemann, H. Fessi, and E. Doelker. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carr. Syst. 22:419–464 (2005).
23. 23. J. S. Woo C. H. Lee C. K. Shim S. J. Hwang 2003 Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031 Pharmacol. Res. 20 24 30 10.1023/A:1022286422439 1:CAS:528:DC%2BD3sXoslKiug%3D%3D J. S. Woo, C. H. Lee, C. K. Shim, and S. J. Hwang. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharmacol. Res. 20:24–30 (2003).
24. 24. S. K. Banerjee C. Jagannath R. L. Hunter A. Dasgupta 2000 Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein Life Sci. 67 2011 2016 11072877 10.1016/S0024-3205(00)00786-4 1:CAS:528:DC%2BD3cXms1CgsL0%3D S. K. Banerjee, C. Jagannath, R. L. Hunter, and A. Dasgupta. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci. 67:2011–2016 (2000).
25. 25. W. M. Pardridge 1998 Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology Cambridge University Press Cambridge W. M. Pardridge. Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology, Cambridge University Press, Cambridge, 1998.
26. 26. E. V. Batrakova D. W. Miller S. Li V. Alakhov A. V. Kabanov W. F. Elmquist 2001 Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies J. Pharmacol. Exp. Ther. 296 551 557 11160643 1:CAS:528:DC%2BD3MXoslejuw%3D%3D E. V. Batrakova, D. W. Miller, S. Li, V. Alakhov, A. V. Kabanov, and W. F. Elmquist. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296:551–557 (2001).
27. 27. W. T. Beck M. C. Cirtain C. J. Glover R. L. Felsted A. R. Safa 1988 Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine Biochem. Biophys. Res. Commun. 153 959 966 2898941 10.1016/S0006-291X(88)81321-4 1:CAS:528:DyaL1cXks1Knt7c%3D W. T. Beck, M. C. Cirtain, C. J. Glover, R. L. Felsted, and A. R. Safa. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem. Biophys. Res. Commun. 153:959–966 (1988).
28. 28. T. Tsuruo H. Iida S. Tsukagoshi Y. Sakurai 1981 Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1967 1972 7214365 1:CAS:528:DyaL3MXitVaks7s%3D T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967–1972 (1981).
29. 29. J. Asperen van O. Tellingen van A. Sparreboom A. H. Schinkel P. Borst W. J. Nooijen J. H. Beijnen 1997 Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Br. J. Cancer 76 1181 1183 9365166 J. van Asperen, O. van Tellingen, A. Sparreboom, A. H. Schinkel, P. Borst, W. J. Nooijen, and J. H. Beijnen. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76:1181–1183 (1997).
30. 30. H. A. Bardelmeijer J. H. Beijnen K. R. Brouwer H. Rosing W. J. Nooijen J. H. Schellens O. Tellingen van 2000 Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein Clin. Cancer Res. 6 4416 4421 11106262 1:CAS:528:DC%2BD3cXovVSgu7Y%3D H. A. Bardelmeijer, J. H. Beijnen, K. R. Brouwer, H. Rosing, W. J. Nooijen, J. H. Schellens, and O. van Tellingen. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6:4416–4421 (2000).
31. 31. E. Friche P. B. Jensen M. Sehested E. J. Demant N. N. Nissen 1990 The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor Cancer Commun. 2 297 303 1976341 1:CAS:528:DyaK3MXlsV2ru7o%3D E. Friche, P. B. Jensen, M. Sehested, E. J. Demant, and N. N. Nissen. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 2:297–303 (1990).
32. 32. V. Alakhov E. Y. Moskaleva E. V. Batrakova A. V. Kabanov 1996 Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer Bioconjug. Chem. 7 209 216 8983343 10.1021/bc950093n 1:CAS:528:DyaK28XhsVGhsb0%3D V. Alakhov, E. Y. Moskaleva, E. V. Batrakova, and A. V. Kabanov. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 7:209–216 (1996).
33. 33. J. Jodoin M. Demeule R. Beliveau 2002 Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols Biochim. Biophys. Acta 1542 149 159 11853888 10.1016/S0167-4889(01)00175-6 1:CAS:528:DC%2BD38Xhtlersbg%3D J. Jodoin, M. Demeule, and R. Beliveau. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta 1542:149–159 (2002).
34. 34. Y. Honda F. Ushigome N. Koyabu S. Morimoto Y. Shoyama T. Uchiumi M. Kuwano H. Ohtani Y. Sawada 2004 Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efflux Br. J. Pharmacol. 143 856 864 15504753 10.1038/sj.bjp.0706008 1:CAS:528:DC%2BD2cXhtFGmurjK Y. Honda, F. Ushigome, N. Koyabu, S. Morimoto, Y. Shoyama, T. Uchiumi, M. Kuwano, H. Ohtani, and Y. Sawada. Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efflux. Br. J. Pharmacol. 143:856–864 (2004).
35. 35. B. Carreno-Gomez and R. Duncan. Compositions with enhanced oral bioavailability. USP 20030211072 (2002).
36. 36. A. Bernkop-Schnürch M. Hornof T. Zoidl 2003 Thiolated polymers–thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates Int. J. Pharm. 260 229 237 12842342 10.1016/S0378-5173(03)00271-0 1:CAS:528:DC%2BD3sXkvFektL4%3D A. Bernkop-Schnürch, M. Hornof, and T. Zoidl. Thiolated polymers–thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. Int. J. Pharm. 260:229–237 (2003).
37. 37. B. M. Johnson, W. N. Charman, and C. J. H. Porter. An in vitro examination of the impact of polyehtylene glycol 400, pluronic P 85 and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on p-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 4 (4) (2002).
38. 38. Q. Shen Y. Lin T. Handa M. Doi M. Sugie K. Wakayama N. Okada T. Fujita A. Yamamoto 2006 Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies Int. J. Pharm. 313 49 56 16500056 10.1016/j.ijpharm.2006.01.020 1:CAS:528:DC%2BD28XjtVGqurg%3D Q. Shen, Y. Lin, T. Handa, M. Doi, M. Sugie, K. Wakayama, N. Okada, T. Fujita, and A. Yamamoto. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 313:49–56 (2006).
39. 39. E. D. Hugger K. L. Audus R. T. Borchardt 2002 Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers J. Pharm. Sci. 91 1980 1990 12210045 10.1002/jps.10175 1:CAS:528:DC%2BD38XmsVSgs7k%3D E. D. Hugger, K. L. Audus, and R. T. Borchardt. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 91:1980–1990 (2002).
40. 40. E. D. Hugger B. L. Novak P. S. Burton K. L. Audus R. T. Borchardt 2002 A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J. Pharm. Sci. 91 1991 2002 12210046 10.1002/jps.10176 1:CAS:528:DC%2BD38XmsVSgs7Y%3D E. D. Hugger, B. L. Novak, P. S. Burton, K. L. Audus, and R. T. Borchardt. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 91:1991–2002 (2002).
41. 41. J. S. Choi B. W. Jo 2004 Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats Int. J. Pharm. 280 221 722 15265561 10.1016/j.ijpharm.2004.05.014 1:CAS:528:DC%2BD2cXlslGhsLk%3D J. S. Choi and B. W. Jo. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int. J. Pharm. 280:221–227 (2004).
42. 42. E. M. Collnot C. Baldes M. F. Wempe J. Hyatt L. Navarro K. J. Edgar U. F. Schaefer C.-M. Lehr 2006 Influence of vitamin E TPGS poly(ethlyene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers J. Control. Release 111 35 40 16410030 10.1016/j.jconrel.2005.11.005 1:CAS:528:DC%2BD28XhslKjtL4%3D E. M. Collnot, C. Baldes, M. F. Wempe, J. Hyatt, L. Navarro, K. J. Edgar, U. F. Schaefer, and C.-M. Lehr. Influence of vitamin E TPGS poly(ethlyene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release 111:35–40 (2006).
43. 43. Y. Shono H. Nishihara Y. Matsuda S. Furukawa N. Okada T. Fujita A. Yamamoto 2004 Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes J. Pharm. Sci. 93 877 885 14999725 10.1002/jps.20017 1:CAS:528:DC%2BD2cXivF2lsbo%3D Y. Shono, H. Nishihara, Y. Matsuda, S. Furukawa, N. Okada, T. Fujita, and A. Yamamoto. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93:877–885 (2004).
44. 44. Y. L. Lo 2003 Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines J. Control. Release 90 37 48 12767705 10.1016/S0168-3659(03)00163-9 1:CAS:528:DC%2BD3sXktVehtb0%3D Y. L. Lo. Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 90:37–48 (2003).
45. 45. H. Zhang M. Yao R. A. Morrison S. Chong 2003 Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats Arch. Pharm. Res. 26 768 772 14560928 1:CAS:528:DC%2BD3sXotFKktro%3D 10.1007/BF02976689 H. Zhang, M. Yao, R. A. Morrison, and S. Chong. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch. Pharm. Res. 26:768–772 (2003).
46. 46. B. D. Rege J. P. Kao J. E. Polli 2002 Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 237 246 12208453 10.1016/S0928-0987(02)00055-6 1:CAS:528:DC%2BD38Xms1ynsro%3D B. D. Rege, J. P. Kao, and J. E. Polli. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16:237–226 (2002).
47. 47. C. Liu J. Wu B. Shi Y. Zhang T. Gao Y. Pei 2006 Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate Drug Dev. Ind. Pharm. 32 115 123 16455610 10.1080/03639040500388573 1:CAS:528:DC%2BD28XhtVeit7g%3D C. Liu, J. Wu, B. Shi, Y. Zhang, T. Gao, and Y. Pei. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev. Ind. Pharm. 32:115–123 (2006).
48. 48. F. Föger H. Hoyer K. Kafedjiiski M. Thaurer A. Bernkop-Schnürch 2006 In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein Biomaterials 27 5855 5860 16919723 10.1016/j.biomaterials.2006.08.004 1:CAS:528:DC%2BD28Xos12qt7c%3D F. Föger, H. Hoyer, K. Kafedjiiski, M. Thaurer, and A. Bernkop-Schnürch. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27:5855–5860 (2006).
49. 49. R. L. Hunter J. McNicholl A. A. Lal 1994 Mechanisms of action of nonionic block copolymer adjuvants AIDS Res. Hum. Retrovir. 10 95 98 R. L. Hunter, J. McNicholl, and A. A. Lal. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retrovir. 10:95–98 (1994).
50. 50. G. Rodeheaver V. Turnbull M. T. Edgerton L. Kurtz R. F. Edlich 1976 Pharmacokinetics of a new skin wound cleanser Am. J. Surg. 132 67 74 782268 10.1016/0002-9610(76)90293-2 1:CAS:528:DyaE28XkvVOntL4%3D G. Rodeheaver, V. Turnbull, M. T. Edgerton, L. Kurtz, and R. F. Edlich. Pharmacokinetics of a new skin wound cleanser. Am. J. Surg. 132:67–74 (1976).
51. 51. E. V. Batrakova S. Li S. V. Vinogradov V. Alakhov D. W. Miller A. V. Kabanov 2001 Mechanism of pluronic effect on p-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization Pharmacol. Exp. Ther. 299 483 493 1:CAS:528:DC%2BD3MXnvV2qsbs%3D E. V. Batrakova, S. Li, S. V. Vinogradov, V. Alakhov, D. W. Miller, and A. V. Kabanov. Mechanism of pluronic effect on p-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. Pharmacol. Exp. Ther. 299:483–493 (2001).
52. 52. D. W. Miller E. V. Batrakova D. O. Waltner V. Alakhov A. V. Kabanov 1997 Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence for two potential pathways for drug absorption Bioconjug. Chem. 8 649 657 9327127 10.1021/bc970118d 1:CAS:528:DyaK2sXlslGntLc%3D D. W. Miller, E. V. Batrakova, D. O. Waltner, V. Alakhov, and A. V. Kabanov. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence for two potential pathways for drug absorption. Bioconjug. Chem. 8:649–657 (1997).
53. 53. C. Jagannath A. Wells M. Mshvildadze M. Olsen E. Sepulveda M. Emanuele R. L. J. Hunter A. Dasgupta 1999 Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer Life Sci. 64 1733 1738 10353627 10.1016/S0024-3205(99)00111-3 1:CAS:528:DyaK1MXisVKjsLk%3D C. Jagannath, A. Wells, M. Mshvildadze, M. Olsen, E. Sepulveda, M. Emanuele, R. L. J. Hunter, and A. Dasgupta. Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci. 64:1733–1738 (1999).
54. 54. A. V. Kabanov E. V. Batrakova D. W. Miller 2003 Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier Adv. Drug Deliv. Rev. 55 1 151 164 12535579 10.1016/S0169-409X(02)00176-X 1:CAS:528:DC%2BD3sXivVWmsg%3D%3D A. V. Kabanov, E. V. Batrakova, and D. W. Miller. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev. 55 (1):151–164 (2003).
55. 55. E. V. Batrakova S. Li D. W. Miller A. V. Kabanov 1999 Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers Pharm. Res. 16 1366 1372 10496651 10.1023/A:1018990706838 1:CAS:528:DyaK1MXmtVKktLc%3D E. V. Batrakova, S. Li, D. W. Miller, and A. V. Kabanov. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:1366–1372 (1999).
56. 56. A. V. Kabanov E. V. Batrakova V. Y. Alakhov 2002 Pluronic block copolymers for overcoming drug resistance in cancer Adv. Drug Deliv. Rev. 54 759 779 12204601 10.1016/S0169-409X(02)00047-9 1:CAS:528:DC%2BD38XmsVeqt74%3D A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54:759–779 (2002).
57. 57. J. Kopecek P. Kopeckova T. Minko Z. Lu 2000 HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur. J. Pharm. Biopharm. 50 61 81 10840193 10.1016/S0939-6411(00)00075-8 1:CAS:528:DC%2BD3cXjslyisr4%3D J. Kopecek, P. Kopeckova, T. Minko, and Z. Lu. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:61–81 (2000).
58. 58. J. Kopecek P. Kopeckova T. Minko Z. R. Lu C. M. Peterson 2001 Water soluble polymers in tumor targeted delivery J. Control. Release 74 147 158 11489491 10.1016/S0168-3659(01)00330-3 1:CAS:528:DC%2BD3MXlslans78%3D J. Kopecek, P. Kopeckova, T. Minko, Z. R. Lu, and C. M. Peterson. Water soluble polymers in tumor targeted delivery. J. Control. Release 74:147–158 (2001).
59. 59. V. Alakhov E. Klinksi S. Li G. Pietrzynski A. Venne E. Batrakova T. Bronitch A. V. Kabanov 1999 Block co-polymer based formulation of doxorubicin. From cell screen to clinical trials Colloids Surf., B Biointerfaces 16 113 134 10.1016/S0927-7765(99)00064-8 1:CAS:528:DyaK1MXnvFylurw%3D V. Alakhov, E. Klinksi, S. Li, G. Pietrzynski, A. Venne, E. Batrakova, T. Bronitch, and A. V. Kabanov. Block co-polymer based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf., B Biointerfaces 16:113–134 (1999).
60. 60. A. Venne S. Li A. Mandeville A. V. Kabanov V. Alakhov 1996 Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells Cancer Res. 56 16 3626 3629 8705995 1:CAS:528:DyaK28XltVKlu7s%3D A. Venne, S. Li, R. Mandeville, A. V. Kabanov, and V. Alakhov. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56 (16):3626–3629 (1996, Aug 15).
61. 61. E. Batrakova S. Lee S. Li A. Venne V. Alakhov A. V. Kabanov 1999 Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells Pharm. Res. 16 1373 1379 10496652 10.1023/A:1018942823676 1:CAS:528:DyaK1MXmtVKktb4%3D E. Batrakova, S. Lee, S. Li, A. Venne, V. Alakhov, and A. V. Kabanov. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1373–1379 (1999).
62. 62. R. Evers M. Kool A. J. Smith L. Deemter van M. Haas de P. Borst 2000 Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport Br. J. Cancer 83 366 374 10917553 10.1054/bjoc.2000.1260 1:CAS:528:DC%2BD3cXlslens7s%3D R. Evers, M. Kool, A. J. Smith, L. van Deemter, M. de Haas, and P. Borst. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport. Br. J. Cancer 83:366–374 (2000).
63. 63. E. V. Batrakova H. Y. Han V. Alakhov D. W. Miller A. V. Kabanov 1998 Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers Pharm. Res. 15 850 855 9647349 10.1023/A:1011964213024 1:CAS:528:DyaK1cXjvFWlsbg%3D E. V. Batrakova, H. Y. Han, V. Alakhov, D. W. Miller, and A. V. Kabanov. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15:850–855 (1998).
64. 64. E. V. Batrakova S. Li Y. Li V. Y. Alakhov A. V. Kabanov 2004 Effect of pluronic P85 on ATPase activity of drug efflux transporters Pharm. Res. 21 2226 2233 15648254 10.1007/s11095-004-7675-5 1:CAS:528:DC%2BD2MXjslyjsw%3D%3D E. V. Batrakova, S. Li, Y. Li, V. Y. Alakhov, and A. V. Kabanov. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 21:2226–2233 (2004).
65. 65. E. Buhleier, W. Wehner, and F. Vögtle. “Cascade”-and “nonskid-chain-like” syntheses of molecular cavity topologies. Synthesis 2:155–158 (1978).
66. 66. E. R. Gillies J. M. Frechet 2005 Dendrimers and dendritic polymers in drug delivery Drug Discov. Today 10 35 43 15676297 10.1016/S1359-6446(04)03276-3 1:CAS:528:DC%2BD2MXoslSqug%3D%3D E. R. Gillies and J. M. Frechet. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 10:35–43 (2005).
67. 67. C. Dufes I. F. Uchegbu A. G. Schatzlein 2005 Dendrimers in gene delivery Adv. Drug Deliv. Rev. 57 2177 2202 16310284 10.1016/j.addr.2005.09.017 1:CAS:528:DC%2BD2MXht12ksb3K C. Dufes, I. F. Uchegbu, and A. G. Schatzlein. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57:2177–202 (2005).
68. 68. V. J. Venditto C. A. Regino M. W. Brechbiel 2005 PAMAM dendrimer based macromolecules as improved contrast agents Mol. Pharm. 2 302 311 16053333 10.1021/mp050019e 1:CAS:528:DC%2BD2MXlvVKrtr8%3D V. J. Venditto, C. A. Regino, and M. W. Brechbiel. PAMAM dendrimer based macromolecules as improved contrast agents. Mol. Pharm. 2:302–311 (2005).
69. 69. A. D’Emanuele R. Jevprasesphant J. Penny D. Attwood 2004 The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability J. Control. Release 95 447 453 15023456 10.1016/j.jconrel.2003.12.006 1:CAS:528:DC%2BD2cXitVKgsLk%3D A. D’Emanuele, R. Jevprasesphant, J. Penny, and D. Attwood. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release 95:447–453 (2004).
70. 70. A. Bernkop-Schnürch 2004 Thiomers: a new generation of mucoadhesive polymers Adv. Drug Deliv. Rev. 57 1569 1582 10.1016/j.addr.2005.07.002 1:CAS:528:DC%2BD2MXhtFSis7fJ A. Bernkop-Schnürch. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57:1569–1582 (2004).
71. 71. M. Werle M. Hoffer 2006 Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine J. Control. Release 111 41 46 16377016 10.1016/j.jconrel.2005.11.011 1:CAS:528:DC%2BD28XhslKjtL8%3D M. Werle and M. Hoffer. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release 111:41–46 (2006).
72. 72. H. L. Luessen, C. O. Rentel, A. F. Kotzé, C.-M. Lehr, A. B. G. de Boer, J. C. Verhoef, and H. E. Junginger. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release 45 (1):15–23 (1997).
73. 73. L. Bromberg 2001 Interactions among proteins and hydrophobically modified polyelectrolytes J. Pharm. Pharmacol. 53 541 547 11341372 10.1211/0022357011775659 1:CAS:528:DC%2BD3MXjsVyiur8%3D L. Bromberg. Interactions among proteins and hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. 53:541–547 (2001).
74. 74. H. L. Luessen C.-M. Lehr C.-O. Rentel A. B. J. Noach A. G. Boer de J. C. Verhoef H. E. Junginger 1994 Bioadhesive polymers for the peroral delivery of peptide drugs J. Control. Release 29 329 338 10.1016/0168-3659(94)90078-7 1:CAS:528:DyaK2cXjtVOitr0%3D H. L. Luessen, C.-M. Lehr, C.-O. Rentel, A. B. J. Noach, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. Bioadhesive polymers for the peroral delivery of peptide drugs. J. Control. Release 29:329–338 (1994).
75. 75. L. Bromberg V. Alakhov 2003 Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers J. Control. Release 88 11 22 12586499 10.1016/S0168-3659(02)00419-4 1:CAS:528:DC%2BD3sXpvF2gug%3D%3D L. Bromberg and V. Alakhov. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Control. Release 88:11–22 (2003).
76. 76. F. Föger T. Schmitz A. Bernkop-Schnürch 2006 In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan Biomaterials 27 4250 4255 16618504 10.1016/j.biomaterials.2006.03.033 1:CAS:528:DC%2BD28XktVWruro%3D F. Föger, T. Schmitz, and A. Bernkop-Schnürch. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27:4250–4255 (2006).
77. 77. F. Föger K. Kafedjiiski H. Hoyer B. Loretz A. Bernkop-Schnürch 2006 Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan J. Drug Target. 15 132 139 10.1080/10611860601140798 1:CAS:528:DC%2BD2sXjt1CgtL4%3D F. Föger, K. Kafedjiiski, H. Hoyer, B. Loretz, and A. Bernkop-Schnürch. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J. Drug Target. 15:132–139 (2006).
78. 78. V. Grabovac and A. Bernkop-Schnürch. Thiolated polymers as effective inhibitors of intestinal Mrp2 efflux pump transporters. Sci. Pharm. 74 (2006).
79. 79. L. Jette G. F. Murphy R. Beliveau 1998 Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment Int. J. Cancer 76 729 737 9610733 10.1002/(SICI)1097-0215(19980529)76:5<729::AID-IJC19>3.0.CO;2-Z 1:CAS:528:DyaK1cXjsFersLk%3D L. Jette, G. F. Murphy, and R. Beliveau. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Int. J. Cancer 76:729–37 (1998).
80. 80. S. Dey M. Ramachandra I. Pastan M. M. Gottesman S. V. Ambudkar 1977 Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein Proc. Natl. Acad. Sci. U. S. A. 94 10594 10599 10.1073/pnas.94.20.10594 S. Dey, M. Ramachandra, I. Pastan, M. M. Gottesman, and S. V. Ambudkar. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 94:10594–10599 (1997).
81. 81. C. Pascaud M. Garrigos S. Orlowski 1998 Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents Biochem. J. 333 351 358 9657975 1:CAS:528:DyaK1cXltVyks78%3D C. Pascaud, M. Garrigos, and S. Orlowski. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem. J. 333:351–358 (1998).
82. 82. A. B. Shapiro K. Fox P. Lam V. Ling 1999 Stimulation of P-glycoprotein mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site Eur. J. Biochem. 259 3 841 850 10092872 10.1046/j.1432-1327.1999.00098.x 1:CAS:528:DyaK1MXhsFejsbg%3D A. B. Shapiro, K. Fox, P. Lam, and V. Ling. Stimulation of P-glycoprotein mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 259 (3):841–850 (1999).
83. 83. M. R. Lugo F. J. Sharom 2005 Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site Biochemisrtry 44 643 655 10.1021/bi0485326 1:CAS:528:DC%2BD2MXis12qsw%3D%3D M. R. Lugo and F. J. Sharom. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemisrtry 44:643–655 (2005).
84. 84. T. W. Loo D. M. Clarke 2002 Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein J. Biol. Chem. 277 44332 44338 12223492 10.1074/jbc.M208433200 1:CAS:528:DC%2BD38Xos1aktL0%3D T. W. Loo and D. M. Clarke. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 277:44332–44338 (2002).
85. 85. T. W. Loo M. C. Bartlett D. M. Clarke 2003 Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding J. Biol. Chem. 278 16 13603 13606 12609990 10.1074/jbc.C300073200 1:CAS:528:DC%2BD3sXjtVSisLc%3D T. W. Loo, M. C. Bartlett, and D. M. Clarke. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278 (16):13603–13606 (2003).
86. 86. P. Crivori B. Reinach D. Pezzetta I. Poggesi 2006 Computational models for identifying potential P-glycoprotein substrates and inhibitors Mol. Pharm. 3 33 44 16686367 10.1021/mp050071a 1:CAS:528:DC%2BD2MXht1yns7zO P. Crivori, B. Reinach, D. Pezzetta, and I. Poggesi. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm. 3:33–44 (2006).
87. 87. R. A. Shilling H. Venter S. Velamakanni A. Bapna B. Woebking S. Shahi H. W. Veen van 2006 New light on multidrug binding by an ATP-binding-cassette transporter Trends Pharmacol. Sci. 27 195 203 16545467 10.1016/j.tips.2006.02.008 1:CAS:528:DC%2BD28Xjs1Wmtb4%3D R. A. Shilling, H. Venter, S. Velamakanni, A. Bapna, B. Woebking, S. Shahi, and H. W. van Veen. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol. Sci. 27:195–203 (2006).
88. 88. S. Ekins R. B. Kim B. F. Leake A. H. Dantzig E. G. Schuetz L. B. Lan K. Yasuda R. L. Shepard M. A. Winter J. D. Schuetz J. H. Wikel S. A. Wrighton 2002 Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein Mol. Pharm. Pharmacol. 61 964 973 10.1124/mol.61.5.964 1:CAS:528:DC%2BD38XjtlGltb4%3D S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L. B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharm. Pharmacol. 61:964–973 (2002).
89. 89. A. Bernkop-Schnürch V. Grabovac 2006 Polymeric efflux pump inhibitors in oral drug delivery Am. J. Drug Deliv. 4 263 272 10.2165/00137696-200604040-00008 A. Bernkop-Schnürch and V. Grabovac. Polymeric efflux pump inhibitors in oral drug delivery. Am. J. Drug Deliv. 4:263–272 (2006).
90. 90. E. M. Collnot C. Baldes M. F. Wempe R. Kappl J. Huttermann J. A. Hyatt K. J. Edgar U. F. Schaefer C. M. Lehr 2007 Mechanism of inhibition of p-glycoprotein mediated efflux by vitamin e TPGS: influence on ATPase activity and membrane fluidity Mol. Pharm. 4 3 465 474 17367162 10.1021/mp060121r 1:CAS:528:DC%2BD2sXivF2is7w%3D E. M. Collnot, C. Baldes, M. F. Wempe, R. Kappl, J. Huttermann, J. A. Hyatt, K. J. Edgar, U. F. Schaefer, and C. M. Lehr. Mechanism of inhibition of p-glycoprotein mediated efflux by vitamin e TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm. 4 (3):465–474 (2007).
91. 91. R. Jevprasesphant J. Penny D. Attwood A. D’Emanuele 2004 Transport of dendrimer nanocarriers through epithelial cells via the transcellular route J. Control. Release 97 259 267 15196753 10.1016/j.jconrel.2004.03.022 1:CAS:528:DC%2BD2cXkslKmtbo%3D R. Jevprasesphant, J. Penny, D. Attwood, and A. D’Emanuele. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Control. Release 97:259–267 (2004).
92. 92. J. Ferte 2000 Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane Eur. J. Biochem. 267 277 294 10632698 10.1046/j.1432-1327.2000.01046.x 1:CAS:528:DC%2BD3cXptl2mtw%3D%3D J. Ferte. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 267:277–294 (2000).
93. 93. Y. Takehisa S. Takaharu T. Eiji N. Osamu 1997 Disposition of polycarbophil calcium (HSR-237) in rats and dogs Iyakuhin Kenkyu 28 23 32 Y. Takehisa, S. Takaharu, T. Eiji, and N. Osamu. Disposition of polycarbophil calcium (HSR-237) in rats and dogs. Iyakuhin Kenkyu 28:23–32 (1997).
94. 94. S. Muranishi 1990 Absorption enhancers Crit. Rev. Ther. Drug Carr. Syst. 7 1 33 1:CAS:528:DyaK3MXivF2ksQ%3D%3D S. Muranishi. Absorption enhancers. Crit. Rev. Ther. Drug Carr. Syst. 7:1–33 (1990).
95. 95. G. L. Schaer L. J. Spaccavento K. F. Browne K. A. Krueger D. Krichbaum J. M. Phelan W. O. Fletcher C. L. Grines S. Edwards M. K. Jolly R. J. Gibbons 1996 Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial Circulation 94 298 307 8759069 1:CAS:528:DyaK28XltF2rsrY%3D G. L. Schaer, L. J. Spaccavento, K. F. Browne, K. A. Krueger, D. Krichbaum, J. M. Phelan, W. O. Fletcher, C. L. Grines, S. Edwards, M. K. Jolly, and R. J. Gibbons. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 94:298–307 (1996).
96. 96. K. Toth L. Bogar I. Juricskay M. Keltai S. Yusuf L. J. Haywood H. J. Meiselman 1997 The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction Clin. Hemorheol. Microcirc. 17 117 125 9255435 1:CAS:528:DyaK1cXhs1SitLY%3D K. Toth, L. Bogar, I. Juricskay, M. Keltai, S. Yusuf, L. J. Haywood, and H. J. Meiselman. The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction. Clin. Hemorheol. Microcirc. 17:117–125 (1997).
97. 97. V. Alakhov E. Klinksi S. Li G. Pietrzynski A. Venne E. Batrakova T. Bronitch A. V. Kabanov 1999 Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials Colloids Surf., B Biointerfaces 16 113 134 10.1016/S0927-7765(99)00064-8 1:CAS:528:DyaK1MXnvFylurw%3D V. Alakhov, E. Klinksi, S. Li, G. Pietrzynski, A. Venne, E. Batrakova, T. Bronitch, and A. V. Kabanov. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf., B Biointerfaces 16:113–134 (1999).
98. 98. J. M. Blonder L. Baird J. C. Fulfs G. J. Rosenthal 1999 Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel Life Sci. 65 261 266 10.1016/S0024-3205(99)00495-6 J. M. Blonder, L. Baird, J. C. Fulfs, and G. J. Rosenthal. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci. 65:261–266 (1999).